论文部分内容阅读
酒石酸长春瑞滨注射剂首次于1989年在法国上市,是治疗晚期乳腺癌和非小细胞肺癌的有效药物之一,但是静脉使用有时会产生严重的静脉炎。我们进行多中心临床研究评价了江苏豪森药业股份有限公司研制的重酒石酸长春瑞滨口服软胶囊的安全性和有效性,现将结果报告如下。一、资料与方法1.对象:入组标准:非小细胞肺癌Ⅲb～Ⅳ期患者;初次化疗患者或凡使用不含紫杉类、健择的化疗方案治疗2～3周期且出现进展者;未经或曾经放疗,总量<60 Gy,且已停
Vinorelbine tartrate is first marketed in France in 1989 as an effective drug for the treatment of advanced breast cancer and non-small cell lung cancer, but intravenous use sometimes produces severe phlebitis. We conducted a multicentre clinical study evaluating the safety and efficacy of vinorelbine tartrate oral soft capsules developed by Jiangsu Howson Pharmaceutical Co., Ltd. The results are reported as follows. First, the data and methods 1. Object: Inclusion criteria: non-small cell lung cancer Ⅲ b ~ Ⅳ patients; initial chemotherapy or those who use the taxane, gemcitabine chemotherapy regimen for 2 to 3 cycles and progress; No or ever had radiotherapy, total <60 Gy, and has stopped